Pharmaceutical - Antibiotics and Infectious diseases, Pricing


Popular Filters

US infectious disease specialists’ prescribing choices for GNIs

US infectious disease specialists’ prescribing choices for GNIs


A majority of US surveyed infectious disease specialists are willing to prescribe novel antibiotics if…

Antibiotics and Infectious diseasesMarkets & MarketingNorth AmericaPharmaceuticalPricing

Bayer in settlement over Cipro pricing


A partial settlement has been reached in a US class action law suit involving the prescription antibiotic…

Antibiotics and Infectious diseasesBayerCiproGenericsLegalNorth AmericaPharmaceuticalPricing

IQWiG finds added benefit for Dificlir in C. difficile infections


Germany's Institute for Quality and Efficiency in Health Care (IQWiG) has now assessed additional information…

Antibiotics and Infectious diseasesAstellas PharmaDificlirEuropePharmaceuticalPricingRegulation

UNITAID market power results in price cuts of up to 80% for HIV/AIDS, TB and malaria products


UNITAID's approach to transform health product markets has delivered price reductions of up to 80% for…

Anti-viralsAntibiotics and Infectious diseasesGenericsGlobalHealthcarePharmaceuticalPricingTropical diseases

IQWiG finds no added proven benefit for Astellas' fidaxomicin in Clostridium difficile infection


In an early benefit assessment under Germany's Act on the Reform of the Market for Medicinal Products…

Antibiotics and Infectious diseasesAstellas PharmaDificidDificlirfidaxomicinPharmaceuticalPricingRegulation

Preliminary NICE guidance negative on Pfizer's Xalkori for lung cancer; backs Colobreathe and Tobi Podhaler for CF


Much to the disappointment of the company, this morning (March 27), UK drugs watchdog the National Institute…

Antibiotics and Infectious diseasesColoBreatheEuropeForest LaboratoriesNovartisOncologyPfizerPharmaceuticalPricingRare diseasesRegulationTobi PodhalerXalkori

NICE "green light" for Novartis' Tobi Podhaler and Forest's Colobreathe


The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in a final draft…

Antibiotics and Infectious diseasesColoBreatheEuropeForest LaboratoriesNovartisPharmaceuticalPricingRare diseasesRegulationTobi Podhaler

Company Spotlight



Back to top